SCN3A and injury: While some observed that treatment with antisense oligodeoxynucleotides targeting Nav1.3 reversed changes in pain responses associated with nerve injury [43,44], others reported that decreasing expression of Nav1.3 was not sufficient to attenuate neuropathic pain behaviours [45,46].